This announcement replaces the original announcement released on 5 January 2015 at 14.30pm (RNS No: 3069B).
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc (the 'Company').
On 31 December 2014, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and ADSs in the Company through the annual reinvestment of dividends paid throughout 2014; calculated using an average price of £13.84 per Ordinary Share and $42.91 per ADS:
Non-Executive Director |
Ordinary Shares |
No. of ADSs |
Sir Christopher Gent |
6,385.452 |
|
Prof Sir Roy Anderson |
1,003.260 |
|
Dr Stephanie Burns |
|
886.521 |
Stacey Cartwright |
256.043 |
|
Lynn Elsenhans |
|
308.422 |
Judy Lewent |
|
208.857 |
Sir Deryck Maughan |
|
2,255.597 |
Dr Daniel Podolsky |
|
1,613.970 |
Tom de Swaan |
1,389.497 |
|
Jing Ulrich |
|
98.139 |
Hans Wijers |
76.661 |
|
The Company and the Non-Executive Directors were informed of these allocations on 5 January 2015.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
15 January 2015
